In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere—from NPR and The Washington Post to Substack and heated exchanges on social media—all circling the same claim: Ozempic might lower the risk of cancer.
Source: Medical Xpress
